Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Urinary Bladder Neoplasms 1Small Cell Lung Carcinoma 1Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Polycystic Ovary Syndrome 1Non-Muscle Invasive Bladder Neoplasms 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Multiple Myeloma 1Lung Neoplasms 1Lower Urinary Tract Symptoms 1Leukemia, Myeloid, Acute 1Leukemia, Biphenotypic, Acute 1Carcinoma, Non-Small-Cell Lung 1Brain Neoplasms 1Adenocarcinoma of Lung 1

Interventions

Carboplatin 36Pemetrexed 28Bevacizumab 26Cisplatin 24Paclitaxel 22Gemcitabine 20Radiotherapy 18Docetaxel 18Erlotinib Hydrochloride 15Gefitinib 11pembrolizumab 6Cetuximab 6capmatinib 5Surgical Procedures, Operative 5Radiosurgery 5aflutinib 4Vinorelbine 4Taxes 4Platinum 4Nivolumab 4Metformin 4pegfilgrastim 3durvalumab 3ceritinib 3apatinib 3Sorafenib 3Radiation 3Neoadjuvant Therapy 3Magnetic Resonance Spectroscopy 3tislelizumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Adenocarcinoma of Lung × Capsules × Clear all
NCT04105270 2025-09-11

RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial

Masonic Cancer Center, University of Minnesota

Phase 2 Recruiting
82 enrolled
Thoracic

Adenocarcinoma of Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡